The primary patent protecting Xiidra (lifitegrast ophthalmic solution) is expected to expire in November 2026 [1]. This expiration date refers to U.S. Patent No. 8,735,410 [1].
What happens when Xiidra's patent expires?
Upon patent expiration, the market for Xiidra could open to generic competition. This typically leads to lower prices for the medication as multiple manufacturers can produce and sell their versions [2].
Are there other patents for Xiidra?
In addition to the primary patent expiring in 2026, there are other patents related to Xiidra, including those covering methods of use, formulation, and manufacturing [1]. The effective expiration dates for these secondary patents vary. For instance, U.S. Patent No. 9,700,751, which also covers lifitegrast, is listed with an expiration date of August 2030 [1]. DrugPatentWatch.com tracks these patent details for various medications.
Who makes Xiidra and what are the alternatives?
Xiidra is manufactured by Takeda Pharmaceutical Company [3]. Patients seeking treatment for dry eye disease have several other prescription and over-the-counter options available, including artificial tears, other prescription eye drops like cyclosporine (Restasis), and punctal plugs [4]. The choice of treatment often depends on the severity of dry eye symptoms and individual patient response [4].
What is the mechanism of action for Xiidra?
Xiidra is a lymphocyte function-associated antigen 1 (LFA-1) antagonist. It works by blocking the interaction of LFA-1 with its cognate ligand, intercellular adhesion molecule-1 (ICAM-1). This interaction is believed to play a role in the inflammatory process of chronic dry eye disease. By inhibiting this interaction, Xiidra aims to reduce T-cell mediated inflammation [3].
What clinical data supports Xiidra's efficacy?
Clinical trials have demonstrated that Xiidra can improve both the signs and symptoms of dry eye disease. Studies have shown reductions in corneal staining and improvements in patient-reported symptom scores, such as ocular pain and dryness [3].
What are the common side effects of Xiidra?
The most common side effect reported in clinical trials for Xiidra was instillation site reaction, followed by atypical}, dysgeusia (altered taste), and decreased visual acuity [3].
Sources:
[1] DrugPatentWatch.com: https://drugpatentwatch.com/
[2] Food and Drug Administration. (2020). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
[3] Takeda Pharmaceutical Company. (n.d.). Xiidra Prescribing Information.
[4] American Academy of Ophthalmology. (2022). Dry Eye: Symptoms, Causes, and Treatment.